지속성 급성호흡곤란증후군 환자에서 "저용량" 글루코코르티코이드 치료 효과에 대한 예비연구
A Preliminary Study on the Effect of "Low-dose" Glucocorticoid Therapy for Patients with Persistent Acute Respiratory Distress Syndrome
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: The role of glucocorticoids for treating persistent acute respiratory distress syndrome (ARDS) is matter of debate. In the previous studies, the side effects of moderate doses of glucocorticoids might have negated positive effects of glucocorticoids. This study aimed at determining the feasibility of administering "low-dose" glucocorticoid to treat the patients who suffer with persistent ARDS. Methods: We retrospectively reviewed the medical records of twelve patients with ARDS of at least seven days` duration and who were treated with "low-dose" glucocorticoid (starting dose of 1 mg/kg) between June 2007 to December 2008. The patients were divided by whether or not they were successfully weaned from the ventilator after glucocorticoid therapy. The baseline characteristics and physiologic parameters were recorded for up to 7 days after starting glucocorticoid therapy. Results: Five patients (42%) were included in the weaned group. There was no significant difference in the clinical characteristics and the physiologic parameters between the two groups on the day of ARDS. Yet the weaned group had a significantly lower Sequential Organ Failure Assessment (SOFA) score, as compared to that of the failed group [3 (3-6) vs 8 (5-12), p = 0.009)] at start of glucocorticoid treatment. After 3 days of glucocorticoid therapy, there was significant improvement in the PEEP, the PaO2/FIO2 ratio, the PCO2, the SOFA score and the Murray Lung Injury Score of the weaned group, as compared to that of the failed group. There were no major neuromuscular side effects from the therapy. Conclusions: This study suggests that the "low-dose" glucocorticoid therapy is feasible and that the SOFA score and the physiologic parameters may assist in determining whether or not to initiate and to continue glucocorticoid therapy for the patients who are suffering with persistent ARDS.
Abstract
Background: The role of glucocorticoids for treating persistent acute respiratory distress syndrome (ARDS) is matter of debate. In the previous studies, the side effects of moderate doses of glucocorticoids might have negated positive effects of glucocorticoids. This study aimed at determining the feasibility of administering "low-dose" glucocorticoid to treat the patients who suffer with persistent ARDS. Methods: We retrospectively reviewed the medical records of twelve patients with ARDS of at least seven days` duration and who were treated with "low-dose" glucocorticoid (starting dose of 1 mg/kg) between June 2007 to December 2008. The patients were divided by whether or not they were successfully weaned from the ventilator after glucocorticoid therapy. The baseline characteristics and physiologic parameters were recorded for up to 7 days after starting glucocorticoid therapy. Results: Five patients (42%) were included in the weaned group. There was no significant difference in the clinical characteristics and the physiologic parameters between the two groups on the day of ARDS. Yet the weaned group had a significantly lower Sequential Organ Failure Assessment (SOFA) score, as compared to that of the failed group [3 (3-6) vs 8 (5-12), p = 0.009)] at start of glucocorticoid treatment. After 3 days of glucocorticoid therapy, there was significant improvement in the PEEP, the PaO2/FIO2 ratio, the PCO2, the SOFA score and the Murray Lung Injury Score of the weaned group, as compared to that of the failed group. There were no major neuromuscular side effects from the therapy. Conclusions: This study suggests that the "low-dose" glucocorticoid therapy is feasible and that the SOFA score and the physiologic parameters may assist in determining whether or not to initiate and to continue glucocorticoid therapy for the patients who are suffering with persistent ARDS.
참고문헌 (29)
- Bernard GR, "The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination", Am J Respir Crit Care Med, 149, pp.818~824 (1994)
- Tomashefski JF Jr, "Pulmonary pathology of the adult respiratory distress syndrome", Clin Chest Med, 11, pp.593~619 (1990)
- Ware LB, "The acute respiratory distress syndrome", N Engl J Med, 342, pp.1334~1349 (2000)
- Cepkova M, "Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome", J Intensive Care Med, 21, pp.119~143 (2006)
- Cheung AM, "Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome", Am J Respir Crit Care Med, 174, pp.538~544 (2006)
- Rubenfeld GD, "Incidence and outcomes of acute lung injury", N Engl J Med, 353, pp.1685~1693 (2005)
- Park WY, "Cytokine balance in the lungs of patients with acute respiratory distress syndrome", Am J Respir Crit Care Med, 164, pp.1896~1903 (2001)
- Martin C, "Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients", Chest, 107, pp.196~200 (1995)
- Braude S, "Chronic adult respiratory distress syndrome--a role for corticosteroids?", Crit Care Med, 20, pp.1187~1189 (1992)
- Hooper RG, "Established ARDS treated with a sustained course of adrenocortical steroids", Chest, 97, pp.138~143 (1990)
- Meduri GU, "Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids", Chest, 100, pp.943~952 (1991)
- Meduri GU, "Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome", Chest, 105, pp.1516~1527 (1994)
- Meduri GU, "Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial", JAMA, 280, pp.159~165 (1998)
- Steinberg KP, "Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome", N Engl J Med, 354, pp.1671~1684 (2006)
- Meduri GU, "Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial", Chest, 131, pp.954~963 (2007)
- "Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network", N Engl J Med, 342, pp.1301~1308 (2000)
- Knaus WA, "APACHE II: a severity of disease classification system", Crit Care Med, 13, pp.818~829 (1985)
- Ferreira FL, "Serial evaluation of the SOFA score to predict outcome in critically ill patients", JAMA, 286, pp.1754~1758 (2001)
- Murray JF, "An expanded definition of the adult respiratory distress syndrome", Am Rev Respir Dis, 138, pp.720~723 (1988)
- Bamberger CM, "Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids", Endocr Rev, 17, pp.245~261 (1996)
- Bernard GR, "High-dose corticosteroids in patients with the adult respiratory distress syndrome", N Engl J Med, 317, pp.1565~1570 (1987)
- Bone RC, "Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome", Chest, 92, pp.1032~1036 (1987)
- Luce JM, "Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock", Am Rev Respir Dis, 138, pp.62~68 (1988)
- Sprung CL, "The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study", N Engl J Med, 311, pp.1137~1143 (1984)
- Weigelt JA, "Early steroid therapy for respiratory failure", Arch Surg, 120, pp.536~540 (1985)
- Confalonieri M, "Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study", Am J Respir Crit Care Med, 171, pp.242~248 (2005)
- Annane D, "Ger-Inf-05 Study Group: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome", Crit Care Med, 34, pp.22~30 (2006)
- 전익수, "스테로이드를 투여한 후기 급성호흡곤란증후군 환자에서 시간경과에 따른 생리학적 지표의 변화", Tuberculosis and Respiratory Diseases, 54(4), pp.429~438 (2003), 대한결핵및호흡기학회
- de Mendonca A, "Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score", Intensive Care Med, 26, pp.915~921 (2000)